Trial Profile
A Randomized, Double-Blind, Placebo- Controlled Study to Investigate the Efficacy and Safety of Injectafer (Ferric Carboxymaltose) as Treatment for Heart Failure With Iron Deficiency
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Mar 2024
Price :
$35
*
At a glance
- Drugs Ferric carboxymaltose (Primary)
- Indications Iron deficiency anaemia
- Focus Registrational; Therapeutic Use
- Acronyms HEART-FID
- Sponsors American Regent; Luitpold Pharmaceuticals
- 19 Mar 2024 According to a CSL Vifor media release, company announced that Health Canada has authorized Ferinject (ferric carboxymaltose) for the intravenous (IV) treatment of iron deficiency anemia in adult and pediatric patients one year of age and older when oral iron preparations are not tolerated or are ineffective, as well as for the treatment of iron deficiency in adult patients with heart failure and New York Heart Association (NYHA) class II/III to improve exercise capacity.
- 26 Aug 2023 Results published in the New England Journal of Medicine.
- 26 Aug 2023 According to American Regent Media Release, results from this trial presented at European Society of Cardiology Congress 2023.